Sanjay Nayak, Chief Strategy Officer of Ocular Therapeutix, Inc., sold 1,897 shares of the company’s common stock on August 24, 2026, for a total of $20,449. The transaction was executed at a weighted average price of $10.78 per share, with individual prices ranging from $10.6425 to $10.8990. The sale was not discretionary; it was conducted to satisfy tax withholding obligations associated with the vesting of restricted stock units on August 22, 2026. The instruction for the automatic sale was adopted on February 21, 2024, following the vesting schedule.
Following the disposal, Nayak retains a direct holding of 326,898 shares of Ocular Therapeutix common stock. The company’s shares closed at $10.36 on August 28, 2026, down 4.25% for the session, while trading at a 52-week high of $16.44 earlier in the year. InvestingPro’s fair value estimate for the stock stands at $11.34.
Ocular Therapeutix is advancing its pipeline, with plans to submit a New Drug Application (NDA) for AXPAXLI in the fourth quarter of 2026. The submission follows alignment with the U.S. Food and Drug Administration regarding the use of specific efficacy and safety data. Analysts have also weighed in on the company’s prospects. H.C. Wainwright raised its price target to $25 while maintaining a buy rating, while Citizens reiterated an outperform rating with a $34 target and projected $12 million in revenue for Dextenza in the second quarter of 2026. Options activity increased by 9,882 call contracts after competitor EyePoint Pharmaceuticals’ DURAVYU failed its Phase 3 trial for wet AMD due to an asymmetrical cohort in the clinical trial.
